LAUSR

The prevalence of retinal neovascular diseases necessitates novel treatments beyond current therapies like laser surgery or anti‐VEGF treatments, which often carry significant side effects. A novel therapeutic approach is introduced using copper‐containing layered double hydroxides (Cu‐LDH) nanozymes integrated with nitric oxide‐releasing molecules (GSHNO), forming Cu‐LDH@GSHNO aimed at combating oxidative stress within the retinal vascular system. Combination of synthetic chemistry and biological testing, Cu‐LDH@GSHNO are synthesized, characterized, and assessed for curative effect in HUVECs and an oxygen‐induced retinopathy (OIR) mouse model. The results indicate that Cu‐LDH@GSHNO demonstrates SOD‐CAT cascade catalytic ability, accompanied with GSH and nitric oxide‐releasing capabilities, which significantly reduces oxidative cell damage and restores vascular function, presenting a dual‐function strategy that enhances treatment efficacy and safety for retinal vascular diseases. The findings encourage further development and clinical exploration of nanozyme‐based therapies, promising a new horizon in therapeutic approaches for managing retinal diseases driven by oxidative stress.